eli lilly's tirzepatide is the leader in weight loss sector Lilly Launches Self-Pay Vials of for Patients With Obesity It is interesting to see

Retatrutide is a triple-agonist weight loss drug thats currently undergoing clinical trials and is not yet FDA approved

Zepbound has been shown to be a possible treatment for obstructive sleep apnea

There was presence of heterogeneity in some comparisons, particularly those involving semaglutide 2.0 mg (ESM Tables 4 and 5)

Higher rates of achieving significant weight loss milestones in clinical studies

These are different molecules with different molecular weights and different receptor binding profiles

Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial